Основная статистика
| CIK | 1023131 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Covance, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| March 2, 2015 |
CVD / Covance, Inc. 15-12B - - 15-12B 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-12213 COVANCE INC. (Exact name of registrant as specified in its |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS 1 d880046ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. 333-18485 Registration No. 333-18487 Registration No. 333-18493 Registration No. 333-29467 Registration No. 333-33185 Registration No. 333-36469 Registration No. 333-90777 Registration No. 333-90779 Registration No. 333-90781 Registration No. 333-36586 Registration No. 333 |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - FORM S-8 POS Form S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS 1 d880046ds8pos.htm S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. 333-18485 Registration No. 333-18487 Registration No. 333-18493 Registration No. 333-29467 Registration No. 333-33185 Registration No. 333-36469 Registration No. 333-90777 Registration No. 333-90779 Registration No. 333-90781 Registration No. 333-36586 Registration No. 333 |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) January 30, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 27, 2015 |
CVD / Covance, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on February 27, 2015 Registration No. |
|
| February 19, 2015 |
AMENDED AND RESTATED COVANCE INC. ARTICLE I Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF COVANCE INC. ARTICLE I Stockholders Section 1.1. Annual Meetings. An annual meeting of stockholders shall be held for the election of directors at such date, time and place either within or without the State of Delaware, or may not be held at any place, but may instead be held solely by means of remote communication, as may be designated by the Board of |
|
| February 19, 2015 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION COVANCE INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF COVANCE INC. FIRST. The name of the corporation is COVANCE INC. SECOND. The address of the corporation’s registered office in the State of Delaware is Corporation Trust Center, 1209 Orange Street in the City of Wilmington, County of New Castle. The name of its registered agent at such address is The Corporation Trust Company. THIRD. |
|
| February 19, 2015 |
8-K 1 form8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 19, 2015 (February 18, 2015) Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other J |
|
| February 19, 2015 |
EX-99.25 2 ruleprovisionnotice.htm NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on March 2, 2015, pursuant to the provisions of Rule 12d2-2 (a). [ X ] 17 CFR 240.12d2-2 |
|
| February 18, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 18, 2015 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organization) (Commi |
|
| February 18, 2015 |
Covance Inc. Stockholders Approve Acquisition by Laboratory Corporation of America Holdings ex99-1.htm Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com Covance Inc. Stockholders Approve Acquisition by Laboratory Corporation of America Holdings Princeton, New Jersey and Burlington, North Carolina - (February 18, 2015) - Covance Inc. (NYSE: CVD) (Covance) and Laboratory Corporation of America® Holdings (NYSE: LH) (LabCorp®) jointly announced that Covance’s sto |
|
| February 17, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 Benefit FAQs (third group) Last Updated: February 16, 2015 Benefits FAQs Tuition Reimbursement: 1. Will employees be required to pay back the tuition reimbursement |
|
| February 17, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 To: LabCorp & Covance Employees From: Steve Anderson & Jared Freedberg Subject: LabCorp/Covance Weekly Integration Update Date: 17 February 2015 Dear Colleagues, W |
|
| February 13, 2015 |
CVD / Covance, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 13, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: Equity Grant FAQs III (Administrative Details) Last Updated: February 12, 2015 Equity Grants - |
|
| February 13, 2015 |
CVD / Covance, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CVD AS OF 12/31/2014 Passive Investment SC 13G/A 1 cvd13gadec14.htm CVD AS OF 12/31/2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6) COVANCE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate |
|
| February 12, 2015 |
CVD / Covance, Inc. / Wellington Management Group LLP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Covance Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 11, 2015 |
CVD / Covance, Inc. / VANGUARD GROUP INC Passive Investment covanceinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Covance Inc Title of Class of Securities: Common Stock CUSIP Number: 222816100 Date of Event Which Requires Filing of this Statement: December 31, 2014 Check the appropriate box to designate |
|
| February 10, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was sent to Covance and LabCorp employees: To: LabCorp & Covance Employees From: Steve Anderson & Jared Freedberg Subject: LabCorp/Cova |
|
| February 10, 2015 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| February 9, 2015 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2015 LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact name of registrant as specified in its charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of inco |
|
| February 9, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 9, 2015 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| February 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 9, 2015 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| February 9, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following letter was mailed to Covance Stockholders: February 9, 2015 Dear Fellow Stockholder: We have previously sent to you proxy material for the important |
|
| February 4, 2015 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| February 4, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was sent to Covance and LabCorp employees: To: LabCorp & Covance Employees From: Steve Anderson & Jared Freedberg Subject: LabCorp/Cova |
|
| February 4, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 4, 2015 Covance Inc. |
|
| February 4, 2015 |
Exhibit 99.1 PRESS RELEASE Investor Relations Contact: Paul Surdez (609) 452-4807 [email protected] www.covance.com COVANCE REPORTS FOURTH QUARTER NET REVENUE OF $634 MILLION, PRO FORMA EPS OF $0.97 AND RECORD ADJUSTED NET ORDERS OF $823 MILLION Princeton, New Jersey, February 4, 2015 — Covance Inc. (NYSE: CVD) today reported results for its fourth quarter ended December 31, 2014. Net revenu |
|
| January 27, 2015 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| January 27, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was sent to Covance senior leaders: Laboratory Corporation of America 531 South Spring Street Burlington, NC 27215 Telephone: 336-436-5 |
|
| January 27, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - 425 425 1 a15-31512425.htm 425 Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance and LabCorp employees: To: LabCorp & Covance Employees From: Steve Anderson & |
|
| January 27, 2015 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| January 26, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - 425 425 1 a15-31511425.htm 425 Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: Important Notice Regarding the Covance Stock Fund On February 18, 2 |
|
| January 23, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - FACT SHEET INFOGRAPHIC Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: LabCorp Laboratory Corporation of America LabCorp has longitudinal data, which measures change |
|
| January 21, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - GENERAL COMPENSATION FAQS Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: General Compensation FAQs (Round 2) Recognition Program: 1. What happens to any accumulated aw |
|
| January 21, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - BENEFIT FAQS Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: Benefit FAQs (second group) Benefits FAQs Covance 401(k) Savings Plan: Will employees receive |
|
| January 20, 2015 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings Pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| January 20, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - INTEGRATION UPDATE Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to employees of Covance and LabCorp: To: LabCorp & Covance Employees From: Steve Anderson & Jared Freedberg Subject: |
|
| January 16, 2015 |
CVD / Covance, Inc. DEFM14A - - DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| January 13, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - INTEGRATION ALL EMPLOYEE MESSAGE Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: All Employee Message Covance Employees, I hope you all have had a safe and happy holiday seaso |
|
| January 12, 2015 |
Exhibit 99.1 Covance Sets February 18, 2015 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By LabCorp PRINCETON, N.J., Jan. 12, 2015 – /PR Newswire/ – Covance Inc. (NYSE: CVD) today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Covance by Laboratory Corporation of America® H |
|
| January 12, 2015 |
Exhibit 99.1 Covance Sets February 18, 2015 As Date of Special Stockholder Meeting To Vote On Its Proposed Acquisition By LabCorp PRINCETON, N.J., Jan. 12, 2015 – /PR Newswire/ – Covance Inc. (NYSE: CVD) today announced it has set a date for a special meeting of its stockholders to consider and vote on the previously announced proposed acquisition of Covance by Laboratory Corporation of America® H |
|
| January 12, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 12, 2015 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| January 12, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 12, 2015 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| January 6, 2015 |
CVD / Covance, Inc. 425 - Merger Prospectus - EQUITY FAQS Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following Frequently Asked Questions were made available to Covance employees: Equity FAQs Round 2 What happens to my unvested stock options at time of closing |
|
| December 29, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - RULE 425 Rule 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| December 29, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - INTEGRATION MEMO Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to employees of Covance and LabCorp: To: LabCorp & Covance Employees From: Steve Anderson & Jared Freedberg Subject: |
|
| December 16, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - EMPLOYEE COMMUNICATION Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: Just One Look: Covance-LabCorp Integration If first impressions matter, then Covance and LabCo |
|
| December 16, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 1 d838825d425.htm 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. Commission File No. for Registration Statement on Form S-4 333-200614 The following press release was issued by LabCorp and Covance on |
|
| December 16, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - PRESS RELEASE Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following joint press release was issued by Covance and LabCorp: HART-SCOTT-RODINO WAITING PERIOD EXPIRES FOR LABCORP ACQUISITION OF COVANCE BURLINGTON, NC and |
|
| December 16, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - COVANCE HSR EXPIRATION CLIENT FAQ Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following Frequently Asked Questions were made available to clients of Covance: Covance HSR Expiration Client FAQ 1. What was announced today? ● We announced t |
|
| December 16, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - HSR ANNOUNCEMENT TO COVANCE EMPLOYEES Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was made available to Covance employees: HSR ANNOUNCEMENT TO COVANCE EMPLOYEES Dear Colleagues: As you may have seen, we recently annou |
|
| December 16, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - PRINCETON TOWN HALL TRANSCRIPT Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following is a transcript of the Princeton Town Hall video: Excerpts from the Princeton Town Hall Joe Herring and Dave King Cautionary Statement Regarding Forw |
|
| December 5, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - FORM 425 Form 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| December 5, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 Form S-4 File No.: 333-200614 The following communication was sent to employees on December 5, 2014: To: All LabCorp & Covance Employees From: Steve Anderson & Jared Freedberg Subject: LabCorp/ |
|
| November 26, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was made available to employees of Covance on November 26, 2014: General Compensation FAQs Cautionary Statement Regarding Forward Looking Statements This communicati |
|
| November 26, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was made available to employees of Covance on November 26, 2014: Benefit FAQs Cautionary Statement Regarding Forward Looking Statements This communication contains “ |
|
| November 26, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was made available to employees of Covance on November 26, 2014: Equity Grant FAQs Cautionary Statement Regarding Forward Looking Statements This communication conta |
|
| November 10, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a transcript of a video for employees of Covance: Employee Video Script Cautionary Statement Regarding Forward Looking Statements This communication contains “forward-looking” |
|
| November 7, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a transcript of the Town Hall Meeting: COVANCE INC. Moderator: Elissa Martini November 3, 2014 10:00 a.m. ET Cautionary Statement Regarding Forward Looking Statements This comm |
|
| November 7, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a transcript of the Town Hall Meeting Session #2: COVANCE INC. Moderator: Elissa Martini November 3, 2014 11:00 a.m. ET Cautionary Statement Regarding Forward Looking Statement |
|
| November 7, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following article was provided to employees of Covance: Combining Forces: Dave King and Joe Herring Meet Princeton and Spring Mill Employees Cautionary Statement Regarding Forward Looking S |
|
| November 7, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a fact sheet of Laboratory Corporation of America Holdings: Cautionary Statement Regarding Forward Looking Statements This communication contains “forward-looking” statements w |
|
| November 7, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a transcript of the Town Hall Meeting Session #1: COVANCE, INC. Moderator: William Klitgaard November 3, 2014 1:00 p.m. ET Cautionary Statement Regarding Forward Looking Statem |
|
| November 5, 2014 |
Covance 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2014 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to clients of Covance on November 3, 2014: Dear [CLIENT NAME] – I am writing to share that this morning we announced that Covance will combine with La |
|
| November 4, 2014 |
EX-2.1 2 ex2-1.htm AGREEMENT AND PLAN OF MERGER Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of November 2, 2014, among LABORATORY CORPORATION OF AMERICA HOLDINGS, NEON MERGER SUB INC. and COVANCE INC. TABLE OF CONTENTS Page ARTICLE I The Merger Section 1.01. The Merger 1 Section 1.02. Closing 1 Section 1.03. Effective Time 2 Section 1.04. Effects of the Merger 2 Section 1.05. Certificate of |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - FORM 425 Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a transcript of the November 3, 2014 video for employees of Covance and LabCorp: Joint CEOs - Employee Video Transcript Dave King · Hello, everyone. I’m Dave King, CEO of LabCo |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - CURRENT REPORT form8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2014 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organizati |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a slide presenation presented to investors of Covance on November 3, 2014: LabCorp to Acquire Covance Creating the World’s Leading Healthcare Company November 3, 2014 FORWARD L |
|
| November 4, 2014 |
EX-99.1 3 ex99-1.htm PRESS RELEASE Exhibit 99.1 LABCORP TO ACQUIRE COVANCE FOR APPROXIMATELY $5.6 BILLION, CREATING WORLD’S LEADING HEALTHCARE DIAGNOSTICS COMPANY · Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share · Combination creates comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics d |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to clients of Covance on November 3, 2014: Dear [CLIENT NAME] – I am writing to share that this morning we announced that Covance will combine with La |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to clients of Covance on November 3, 2014: 1. What was announced? ● Covance announced that it is combining with Laboratory Corporation of America® Hol |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following is a slide presentation presented to employees of Covance on November 3, 2014: Creating the world’s leading health diagnostics company Covance Joins With LabCorp 3 November 2014 C |
|
| November 4, 2014 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER dated as of November 2, 2014, among LABORATORY CORPORATION OF AMERICA HOLDINGS, NEON MERGER SUB INC. and COVANCE INC. TABLE OF CONTENTS Page ARTICLE I The Merger Section 1.01. The Merger 1 Section 1.02. Closing 1 Section 1.03. Effective Time 2 Section 1.04. Effects of the Merger 2 Section 1.05. Certificate of Incorporation and Bylaws 2 Section 1.06. Directo |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to clients of Covance on November 3, 2014: Dear [CLIENT NAME] – I am writing to share that this morning we announced that Covance will combine with La |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to employees of Covance on November 3, 2014: 1. What was announced? Covance announced that it has entered into a definitive agreement to combine with |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to suppliers of Covance on November 3, 2014: Dear [NAME / INSERT STANDARD GREETING]: I’m writing to share an important and exciting development: Covan |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to clients of Covance on November 3, 2014: Dear [CLIENT NAME] – I am writing to share that this morning we announced that Covance will combine with La |
|
| November 4, 2014 |
Exhibit 99.1 LABCORP TO ACQUIRE COVANCE FOR APPROXIMATELY $5.6 BILLION, CREATING WORLD’S LEADING HEALTHCARE DIAGNOSTICS COMPANY · Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share · Combination creates comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics development and commercialization · |
|
| November 4, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following letter was first sent to employees of Covance on November 3, 2014: Subject: A Note from David King, CEO of LabCorp November 3, 2014 Dear Covance Employees, I want to take this opp |
|
| November 4, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2014 Covance Inc. (Exact name of Registrant as Specified in its Charter) Delaware 1-12213 22-3265977 (State or Other Jurisdiction of Incorporation or Organization) (Commis |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 NOVEMBER 03, 2014 / 1:00PM, LH - Laboratory Corporation of America Holdings to Acquire Covance Call CORPORATE PARTICIPANTS Steve Anderson Laboratory Corporation of America Holdings - VP of IR D |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following letter was first sent to employees of Covance on November 3, 2014: Dear colleagues: I’m writing to share some exciting news. Covance has entered into a definitive agreement to com |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to clients of Covance on November 3, 2014: Dear [CLIENT NAME] – I am writing to share that this morning we announced that Covance will combine with La |
|
| November 4, 2014 |
CVD / Covance, Inc. 425 - Merger Prospectus - Filed by Covance Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Exchange Act of 1934 Subject Company: Covance Inc. Commission File No.: 1-12213 The following communication was first sent to suppliers of Covance on November 3, 2014: 1. What was announced today? ● Covance announced that it is combining with Laboratory Corporation of Amer |
|
| November 3, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| November 3, 2014 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 3, 2014 Covance Inc. |
|
| November 3, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| November 3, 2014 |
Exhibit 10.1 Exhibit 10.1 EXECUTION VERSION MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED BANK OF AMERICA, N.A. One Bryant Park New York, New York 10036 WELLS FARGO SECURITIES, LLC Duke Energy Center 550 South Tryon Street Charlotte, North Carolina 28202 WELLS FARGO BANK, NATIONAL ASSOCIATION 301 South College Street Charlotte, North Carolina 28288 CONFIDENTIAL November 2, 2014 Laboratory Cor |
|
| November 3, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 1 d814961d425.htm 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. (Commission File No. 001-12213) The following is a transcript of a video for employees of LabCorp and Covance: Joint CEOs - Employee V |
|
| November 3, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 2, 2014 (Date of earliest event reported) LABORATORY CORPORATION OF AMERICA HOLDINGS (Exact Name of Registrant as Specified in its Charter) Delaware 1-11353 13-3757370 (State or other jurisdiction of Incorporation) (Commission File Number) (I. |
|
| November 3, 2014 |
EX-2.1 2 d814905dex21.htm EXHIBIT 2.1 Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER dated as of November 2, 2014, among LABORATORY CORPORATION OF AMERICA HOLDINGS, NEON MERGER SUB INC. and COVANCE INC. TABLE OF CONTENTS Page ARTICLE I The Merger Section 1.01. The Merger 1 Section 1.02. Closing 1 Section 1.03. Effective Time 2 Section 1.04. Effects of the Merger 2 Section 1.05. Certifi |
|
| November 3, 2014 |
Exhibit 99.1 Exhibit 99.1 LABCORP TO ACQUIRE COVANCE FOR APPROXIMATELY $5.6 BILLION, CREATING WORLD’S LEADING HEALTHCARE DIAGNOSTICS COMPANY • Covance shareholders to receive cash and LabCorp shares currently valued at $105.12 per Covance share • Combination creates comprehensive healthcare diagnostics company offering customers end-to-end solutions for drug and diagnostics development and commerc |
|
| November 3, 2014 |
EX-99.1 2 a14-234471ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS THIRD QUARTER NET REVENUE GROWTH OF 3.4% TO $627 MILLION, PRO FORMA EPS GROWTH OF 18.2% to $0.98 AND ADJUSTED NET ORDERS OF $752 MILLION — FY2014 Pro Forma EPS updated to the range of $3.78 to $3.81 reflecting significant strengthening of the US Dollar— Princeton, N |
|
| November 3, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 1 d814961d425.htm 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. (Commission File No. 001-12213) The following Frequently Asked Questions were made available to LabCorp Employees: LABCORP EMPLOYEE FA |
|
| November 3, 2014 |
LH / Laboratory Corp. of America Holdings 425 - Merger Prospectus - 425 425 Filed by Laboratory Corporation of America Holdings pursuant to Rule 425 under the Securities Act of 1933, as amended and deemed filed pursuant to Rule 14a-12 of the Securities Exchange Act of 1934, as amended Subject Company: Covance Inc. |
|
| August 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 a14-13860110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2014 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commiss |
|
| July 30, 2014 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS SECOND QUARTER NET REVENUE GROWTH OF 8.0% TO $639 MILLION, PRO FORMA EPS GROWTH OF 21.5% to $0.95 AND ADJUSTED NET ORDERS OF $773 MILLION — Updates FY2014 Pro Forma EPS Target to $3.78 to $3.92 — Princeton, New Jersey, July 29, 2014 — Covance Inc. (NYSE: CVD) today reported results for its second quarter |
|
| July 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 29, 2014 Covance Inc. |
|
| June 20, 2014 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (X) ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-12213 A. Full title of the plan and address of the plan, |
|
| June 6, 2014 |
Exhibit 10.1 Execution Version CUSIP #22281RAA2 THIRD AMENDED AND RESTATED CREDIT AGREEMENT by and among COVANCE INC. and THE GUARANTORS PARTY HERETO and THE LENDERS PARTY HERETO and PNC BANK, NATIONAL ASSOCIATION, as Agent Dated as of June 2, 2014 PNC CAPITAL MARKETS LLC, and J.P. MORGAN SECURITIES, LLC, as Joint Lead Arrangers and Joint Bookrunners JPMORGAN CHASE BANK, N.A., as Syndication Agent |
|
| June 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 2, 2014 Covance Inc. |
|
| May 30, 2014 |
COVANCE INC. 2014 EMPLOYEE EQUITY PARTICIPATION PLAN Exhibit 4.1 COVANCE INC. 2014 EMPLOYEE EQUITY PARTICIPATION PLAN 1. PURPOSE The Covance Inc. 2014 Employee Equity Participation Plan (the “Plan”) is intended to (i) encourage executive, managerial, technical and other Employees of Covance Inc. (the “Corporation” or “Company”) or a Subsidiary (as defined below) to become owners of stock of the Corporation in order to increase their proprietary inte |
|
| May 30, 2014 |
As filed with the Securities and Exchange Commission on May 30, 2014 Registration No. |
|
| May 9, 2014 |
COVANCE INC. 2014 EMPLOYEE EQUITY PARTICIPATION PLAN Exhibit 10.1 COVANCE INC. 2014 EMPLOYEE EQUITY PARTICIPATION PLAN 1. PURPOSE The Covance Inc. 2014 Employee Equity Participation Plan (the “Plan”) is intended to (i) encourage executive, managerial, technical and other Employees of Covance Inc. (the “Corporation” or “Company”) or a Subsidiary (as defined below) to become owners of stock of the Corporation in order to increase their proprietary int |
|
| May 9, 2014 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 6, 2014 Covance Inc. |
|
| May 5, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2014 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 COVA |
|
| May 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 1, 2014 Covance Inc. |
|
| May 1, 2014 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FIRST QUARTER NET REVENUE GROWTH OF 6.9% TO $620 MILLION, PRO FORMA EPS GROWTH OF 20.1% to $0.90 AND ADJUSTED NET ORDERS OF $710 MILLION Princeton, New Jersey, May 1, 2014 — Covance Inc. (NYSE: CVD) today reported results for its first quarter ended March 31, 2014. Net revenue was $620 million, represent |
|
| March 24, 2014 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 27, 2014 |
10-K 1 a2218224z10-k.htm 10-K QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 Commission File Number: 1-12213 COVANCE INC. (Exact name of Registrant as specified in its Ch |
|
| February 27, 2014 |
EX-21 2 a2218224zex-21.htm EX-21 QuickLinks - Click here to rapidly navigate through this document Exhibit 21 COVANCE INC. SUBSIDIARY LIST CJB Inc. Delaware Covance (Argentina) SA Argentina Covance (Asia) Pte. Ltd. Singapore Covance (Canada) Inc. Canada Covance Antibody Services Inc. California Covance Asia-Pacific Inc. Delaware Covance Bioanalytical Services LLC Delaware Covance Central Laborator |
|
| February 24, 2014 |
EX-10.2 4 a14-62551ex10d2.htm EX-10.2 Exhibit 10.2 COVANCE INC. RESTRICTED STOCK AGREEMENT (Performance Share) 201 Employee Equity Participation Plan (201 Award) RESTRICTED STOCK AGREEMENT dated as of , 201 (the “Agreement”) between COVANCE INC., a Delaware corporation (“Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, and (the “Employee”). W I T N E S S E T H: A. WHEREAS, t |
|
| February 24, 2014 |
8-K 1 a14-625518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 18, 2014 Covance Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 1-12213 22-3265977 (State or other jurisdiction (Commission (IRS |
|
| February 24, 2014 |
Exhibit 10.1 [EMPLOYEE] [ADDRESS] [Grant Date: ] COVANCE INC. NON-QUALIFIED STOCK OPTION AWARD 201 Employee Equity Participation Plan NON-QUALIFIED STOCK OPTION AWARD granted by COVANCE INC., a Delaware Company (the “Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, to the “Employee”. A. WHEREAS, the Employee is now employed by the Company, or a corporation which is a “subsid |
|
| February 24, 2014 |
COVANCE INC. A Delaware corporation AMENDED AND RESTATED BY-LAWS Exhibit 3.1 COVANCE INC. A Delaware corporation AMENDED AND RESTATED BY-LAWS COVANCE INC. A Delaware corporation AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 Section 1.01 Annual Meetings 1 Section 1.02 Special Meetings 1 Section 1.03 Notice of Meetings 1 Section 1.04 Business Transacted at Special Meetings of Stockholders 1 Section 1.05 Adjournments 2 Section 1.06 Q |
|
| February 14, 2014 |
CVD / Covance, Inc. / Wellington Management Group LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Covance Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 12, 2014 |
CVD / Covance, Inc. / VANGUARD GROUP INC Passive Investment convanceinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Covance Inc Title of Class of Securities: Common Stock CUSIP Number: 222816100 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate |
|
| February 11, 2014 |
CVD / Covance, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CVD AS OF 12/31/2013 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* COVANCE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is file |
|
| February 7, 2014 |
CVD / Covance, Inc. / BROWN ADVISORY INC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 4, 2014 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FOURTH QUARTER NET REVENUE OF $623 MILLION, PRO FORMA EPS OF $0.87 AND ADJUSTED NET ORDERS OF $769 MILLION — Issues FY2014 Pro Forma EPS Target of $3.65 to $4.00 — Princeton, New Jersey, February 4, 2014 — Covance Inc. (NYSE: CVD) today reported results for its fourth quarter and year ended December 31, |
|
| February 4, 2014 |
8-K 1 a14-497618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 4, 2014 Covance Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 1-12213 22-3265977 (State or other jurisdiction (Commission (IRS E |
|
| November 20, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 15, 2013 Covance Inc. |
|
| November 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 a13-19468110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2013 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Co |
|
| October 29, 2013 |
EX-99.1 2 a13-230361ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS THIRD QUARTER NET REVENUE OF $607 MILLION, PRO FORMA EPS OF $0.83 AND ADJUSTED NET ORDERS OF $732 MILLION — Raises FY2013 Pro Forma EPS Target to approximately $3.20 — Princeton, New Jersey, October 29, 2013 — Covance Inc. (NYSE: CVD) today reported results for its |
|
| October 29, 2013 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 29, 2013 Covance Inc. |
|
| October 23, 2013 |
October 23, 2013 Mr. James Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance Securities and Exchange Commission 450 Fifth Street, N.W. Judiciary Plaza Washington, D.C. 20549 Re: Covance Inc. Form 10-Q for the Quarterly Period Ended June 30, 2013 File Number: 001-12213 Via EDGAR Transmission Dear Mr. Rosenberg: Set forth below are the responses of Covance Inc. (the “Compan |
|
| October 8, 2013 |
SECOND AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 10.2 Execution Version SECOND AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT This SECOND AMENDMENT TO SECOND AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is dated as of October 2, 2013 and is made by and among COVANCE INC., a Delaware corporation (the “Borrower”), each of the Guarantors and the Lenders signatory hereto, and PNC BANK, NATIONAL ASSOCIATION, as agent (t |
|
| October 8, 2013 |
Exhibit 10.1 Execution Copy COVANCE INC. $250,000,000 $15,000,000 3.25% Senior Notes, Series 2013A, due November 15, 2018 $50,000,000 3.90% Senior Notes, Series 2013B, due November 15, 2020 $90,000,000 4.50% Senior Notes, Series 2013C, due November 15, 2023 $95,000,000 4.65% Senior Notes, Series 2013D, due November 15, 2025 NOTE PURCHASE AGREEMENT Dated as of October 2, 2013 TABLE OF CONTENTS SECT |
|
| October 8, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 2, 2013 Covance Inc. |
|
| September 27, 2013 |
September 27, 2013 Mr. James Rosenberg Senior Assistant Chief Accountant Division of Corporation Finance Securities and Exchange Commission 450 Fifth Street, N.W. Judiciary Plaza Washington, D.C. 20549 Re: Covance Inc. Form 10-Q for the Quarterly Period Ended June 30, 2013 Filed August 1, 2013 File Number: 001-12213 Via EDGAR Transmission Dear Mr. Rosenberg: Please refer to your comment letter dat |
|
| August 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2013 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 COVAN |
|
| July 30, 2013 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 30, 2013 Covance Inc. |
|
| July 30, 2013 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS SECOND QUARTER NET REVENUE OF $592 MILLION, PRO FORMA EPS OF $0.78 AND RECORD ADJUSTED NET ORDERS OF $776 MILLION — Raises FY2013 Pro Forma EPS Target to $3.10 to $3.20 — Princeton, New Jersey, July 30, 2013 — Covance Inc. (NYSE: CVD) today reported results for its second quarter ended June 30, 2013. Net |
|
| June 26, 2013 |
As filed with the Securities and Exchange Commission on June 26, 2013 Registration No. |
|
| June 26, 2013 |
COVANCE INC. 2013 EMPLOYEE EQUITY PARTICIPATION PLAN Exhibit 4.1 COVANCE INC. 2013 EMPLOYEE EQUITY PARTICIPATION PLAN 1. PURPOSE The Covance Inc. 2013 Employee Equity Participation Plan (the “Plan”) is intended to (i) encourage executive, managerial, technical and other Employees of Covance Inc. (the “Corporation” or “Company”) or a Subsidiary (as defined below) to become owners of stock of the Corporation in order to increase their proprietary inte |
|
| June 21, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (X) ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-12213 A. Full title of the plan and address of the plan, |
|
| May 13, 2013 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 7, 2013 Covance Inc. |
|
| May 13, 2013 |
COVANCE INC. 2013 EMPLOYEE EQUITY PARTICIPATION PLAN Exhibit 10.1 COVANCE INC. 2013 EMPLOYEE EQUITY PARTICIPATION PLAN 1. PURPOSE The Covance Inc. 2013 Employee Equity Participation Plan (the “Plan”) is intended to (i) encourage executive, managerial, technical and other Employees of Covance Inc. (the “Corporation” or “Company”) or a Subsidiary (as defined below) to become owners of stock of the Corporation in order to increase their proprietary int |
|
| May 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2013 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 COVA |
|
| May 1, 2013 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FIRST QUARTER NET REVENUE GROWTH OF 9.3% TO $580 MILLION, PRO FORMA EPS OF $0.75 AND ADJUSTED NET ORDERS OF $716 MILLION — Raises FY2013 Pro Forma EPS Target to $3.00 to $3.20 — Princeton, New Jersey, May 1, 2013 – Covance Inc. (NYSE: CVD) today reported results for its first quarter ended March 31, 2013 |
|
| May 1, 2013 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 1, 2013 Covance Inc. |
|
| March 25, 2013 |
DEF 14A 1 a2213437zdef14a.htm DEF 14A QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary P |
|
| February 27, 2013 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 21 COVANCE INC. |
|
| February 27, 2013 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 25, 2013 |
COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2013 Award) Exhibit 10.1 COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2013 Award) RESTRICTED STOCK AGREEMENT dated as of February 19, 2013 (the “Agreement”) between COVANCE INC., a Delaware corporation (“Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, and Alison A. Cornell (the “Employee”). W I T N E S S E T H: A. WHEREAS, the Employee is currently e |
|
| February 25, 2013 |
EX-3.1 2 a13-58171ex3d1.htm EX-3.1 Exhibit 3.1 COVANCE INC. A Delaware corporation (formerly known as Corning Pharmaceutical Services Inc.) AMENDED AND RESTATED BY-LAWS (effective June 30, 2013) COVANCE INC. A Delaware corporation AMENDED AND RESTATED BY-LAWS TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1 Section 1.01 Annual Meetings 1 Section 1.02 Special Meetings 1 Section 1.03 Notice of Meetin |
|
| February 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 19, 2013 Covance Inc. |
|
| February 14, 2013 |
CVD / Covance, Inc. / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Covance Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 7, 2013 |
CVD / Covance, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 6, 2013 |
CVD / Covance, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CVD AS OF 12/31/12 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* COVANCE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is file |
|
| January 24, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 24, 2013 Covance Inc. |
|
| January 24, 2013 |
EX-99.1 2 a13-35441ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FOURTH QUARTER PRO FORMA NET REVENUE OF $561 MILLION, PRO FORMA EPS OF $0.73 AND ADJUSTED NET ORDERS OF $769 MILLION — Issues FY2013 Pro Forma EPS Target of $2.85 to $3.15 — Princeton, New Jersey, January 24, 2013 — Covance Inc. (NYSE: CVD) today reported results for |
|
| November 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2012 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 |
|
| November 6, 2012 |
CVD / Covance, Inc. / BROWN ADVISORY INC - BROWN ADVISORY INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) October 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| November 5, 2012 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS THIRD QUARTER PRO FORMA NET REVENUE OF $542 MILLION, PRO FORMA EPS OF $0.72 AND ADJUSTED NET ORDERS OF $701 MILLION — FY2012 Pro Forma EPS Target now $2.65 to $2.70 versus previous range of $2.50 to $2.70 — Princeton, New Jersey, November 5, 2012 — Covance Inc. (NYSE: CVD) today reported results for its |
|
| November 5, 2012 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 5, 2012 Covance Inc. |
|
| August 3, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2012 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 COVAN |
|
| July 31, 2012 |
COVANCE INC. NON-EMPLOYEE DIRECTORS DEFERRED STOCK PLAN EX-4.3 2 a12-162461ex4d3.htm EX-4.3 Exhibit 4.3 COVANCE INC. NON-EMPLOYEE DIRECTORS DEFERRED STOCK PLAN Section 1. Purpose of the Plan. The purpose of the Covance Inc. Non-Employee Directors Deferred Stock Plan (the “Plan”) is to assist the Company in attracting and retaining valued Non-Employee Directors by offering them a greater stake in the Company’s success and a closer identity with it, and |
|
| July 31, 2012 |
EX-4.3 2 a12-161801ex4d3.htm EX-4.3 Exhibit 4.3 COVANCE 401(k) SAVINGS PLAN (As Amended and Restated Effective April 1, 2007) COVANCE 401(k) SAVINGS PLAN (As Amended and Restated Effective April 1, 2007) Table of Contents Page ARTICLE I. DEFINITIONS 1 ARTICLE II. PARTICIPATION 14 2.1. Eligibility Requirements 14 2.2. Election to Make Elective Deferral Contributions 14 2.3. Ineligible Employees 15 |
|
| July 31, 2012 |
As filed with the Securities and Exchange Commission on July 31, 2012 Registration No. |
|
| July 31, 2012 |
As filed with the Securities and Exchange Commission on July 31, 2012 Registration No. |
|
| July 25, 2012 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS SECOND QUARTER PRO FORMA NET REVENUE OF $538 MILLION, PRO FORMA EPS OF $0.65 AND ADJUSTED NET ORDERS OF $701 MILLION Princeton, New Jersey, July 25, 2012 — Covance Inc. (NYSE: CVD) today reported results for its second quarter ended June 30, 2012. On a GAAP basis, net revenue was $543 million. Excluding |
|
| July 25, 2012 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 25, 2012 Covance Inc. |
|
| June 22, 2012 |
COVANCE INC. ANNUAL BONUS PLAN Exhibit 10.1 COVANCE INC. ANNUAL BONUS PLAN 1. Purpose: The purpose of the Covance Inc. Annual Bonus Plan (as amended, modified or supplemented, from time to time, the “Plan”) is to incent both Company and the individual performance of eligible employees of Covance Inc. (“Covance”) and its subsidiaries (collectively, the “Company”). The Plan does not constitute an amendment, supplement or modifica |
|
| June 22, 2012 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-12213 A. Full title of the plan and address of the plan, if d |
|
| June 22, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 18, 2012 Covance Inc. |
|
| May 14, 2012 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 8, 2012 Covance Inc. |
|
| May 14, 2012 |
COVANCE INC. NON-EMPLOYEE DIRECTORS DEFERRED STOCK PLAN Exhibit 10.1 COVANCE INC. NON-EMPLOYEE DIRECTORS DEFERRED STOCK PLAN Section 1. Purpose of the Plan. The purpose of the Covance Inc. Non-Employee Directors Deferred Stock Plan (the “Plan”) is to assist the Company in attracting and retaining valued Non-Employee Directors by offering them a greater stake in the Company’s success and a closer identity with it, and to encourage ownership of the Compa |
|
| May 14, 2012 |
Exhibit 10.2 [ ] [ ] [ ] Dear [ ]: On , , pursuant to the Non-Employee Directors Deferred Stock Plan (the “Plan”), the Board of Directors (the “Board”) approved a grant to you of Deferred Shares (the “Award” or the “Deferred Shares”). Your Award is subject to the terms and conditions of the Plan (which are incorporated herein by reference) and this letter agreement (the “Agreement”). In the event |
|
| May 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 8, 2012 Covance Inc. |
|
| May 4, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q 10-Q 1 a12-6655110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2012 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commiss |
|
| May 2, 2012 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FIRST QUARTER NET REVENUE GROWTH OF 5.7% TO $531M, EPS OF $0.60, AND ADJUSTED NET ORDERS OF $704M — Announces Restructuring Actions to Improve Early Development Profitability — Princeton, New Jersey, May 2, 2012 — Covance Inc. (NYSE: CVD) today reported financial results for its first quarter ended March |
|
| May 2, 2012 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 2, 2012 Covance Inc. |
|
| March 26, 2012 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 7, 2012 Covance Inc. |
|
| March 13, 2012 |
Exhibit 10.1 Execution Version CUSIP #22281RAA2 SECOND AMENDED AND RESTATED CREDIT AGREEMENT by and among COVANCE INC. and THE GUARANTORS PARTY HERETO and THE LENDERS PARTY HERETO and PNC BANK, NATIONAL ASSOCIATION, as Agent Dated as of March 7, 2012 PNC CAPITAL MARKETS LLC, and J.P. MORGAN SECURITIES, LLC, as Joint Lead Arrangers and Joint Bookrunners JPMORGAN CHASE BANK, N.A., as Syndication Age |
|
| February 28, 2012 |
10-K 1 a2207272z10-k.htm 10-K QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 Commission File Number: 1-12213 COVANCE INC. (Exact name of Registrant as specified in its Ch |
|
| February 28, 2012 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 21 COVANCE INC. |
|
| February 28, 2012 |
COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2011 Award) Exhibit 10.48 COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2011 Award) RESTRICTED STOCK AGREEMENT dated as of February 17, 2011 (the “Agreement”) between COVANCE INC., a Delaware corporation (“Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, and (the “Employee”). W I T N E S S E T H: A. WHEREAS, the Employee is currently employed by the Co |
|
| February 24, 2012 |
[Grant Date: ] COVANCE INC. NON-QUALIFIED STOCK OPTION AWARD 20 Employee Equity Participation Plan EX-10.2 3 a11-312781ex10d2.htm EX-10.2 Exhibit 10.2 [Grant Date: ] COVANCE INC. NON-QUALIFIED STOCK OPTION AWARD 20 Employee Equity Participation Plan NON-QUALIFIED STOCK OPTION AWARD granted by COVANCE INC., a Delaware Company (the “Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, to the “Employee”. A. WHEREAS, the Employee is now employed by the Company, or a corporation w |
|
| February 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 20, 2012 Covance Inc. |
|
| February 24, 2012 |
EX-10.1 2 a11-312781ex10d1.htm EX-10.1 Exhibit 10.1 Form of Letter Agreement for the following executives: Richard Cimino, William Klitgaard, James Lovett, Deborah Tanner and John Watson February 21, 2012 Name / Address Re: Employment Letter Agreement (the “Agreement”) Dear [Name]: Position As [Job Title], you will report directly to the Chief Executive Officer of Covance Inc. (“Covance” or the “C |
|
| February 14, 2012 |
CVD / Covance, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ - CVD AS OF 12/31/2011 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* COVANCE INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is file |
|
| February 10, 2012 |
CVD / Covance, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) COVANCE INC (Name of Issuer) COM (Title of Class of Securities) 222816100 (CUSIP Number) January 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] |
|
| February 1, 2012 |
CVD / Covance, Inc. / BROWN ADVISORY INC - BROWN ADVISORY HOLDINGS INCORPORATED Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| January 26, 2012 |
CVD / Covance, Inc. / WELLS FARGO & COMPANY/MN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) COVANCE INC (Name of Issuer) COM (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] |
|
| January 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 25, 2012 Covance Inc. |
|
| January 25, 2012 |
COVANCE BOARD AUTHORIZES $300 MILLION STOCK BUYBACK Exhibit 99.2 PRESS RELEASE Contact: Paul Surdez (609) 452 4807 www.covance.com COVANCE BOARD AUTHORIZES $300 MILLION STOCK BUYBACK Princeton, New Jersey, January 25, 2012 — Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $300 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remainin |
|
| January 25, 2012 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FOURTH QUARTER REVENUE OF $532M, GAAP EPS OF $0.35, PRO FORMA EPS OF $0.73, AND ADJUSTED NET ORDERS OF $759M — Issues 2012 Revenue and EPS Guidance — Princeton, New Jersey, January 25, 2012 — Covance Inc. (NYSE: CVD) today reported GAAP earnings for its fourth quarter ended December 31, 2011 of $0.35 per |
|
| January 10, 2012 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE TO PRESENT AT THE 30th ANNUAL JP MORGAN HEALTHCARE CONFERENCE -Company reiterates full year 2011 Revenue and Pro Forma EPS guidance- Princeton, New Jersey, January 9, 2012 — Covance Inc. (NYSE: CVD) today announced that its Chairman and CEO, Joe Herring, will present at the 30th Annual J.P. Morgan Healthcare Con |
|
| January 10, 2012 |
Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 9, 2012 Covance Inc. |
|
| December 12, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 6, 2011 Covance Inc. |
|
| November 4, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2011 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 |
|
| November 2, 2011 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 2, 2011 Covance Inc. |
|
| November 2, 2011 |
COVANCE REPORTS THIRD QUARTER REVENUE OF $543 MILLION, GAAP EPS OF $0.67, AND PRO FORMA EPS OF $0.71 Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS THIRD QUARTER REVENUE OF $543 MILLION, GAAP EPS OF $0.67, AND PRO FORMA EPS OF $0.71 Princeton, New Jersey, November 2, 2011 — Covance Inc. (NYSE: CVD) today reported GAAP earnings for its third quarter ended September 30, 2011 of $0.67 per diluted share. Included in third quarter r |
|
| August 3, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2011 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 COVAN |
|
| July 27, 2011 |
Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS SECOND QUARTER REVENUE OF $518 MILLION, GAAP EPS OF $0.61, AND PRO FORMA EPS OF $0.66 Princeton, New Jersey, July 27, 2011 – Covance Inc. (NYSE: CVD) today reported GAAP earnings for its second quarter ended June 30, 2011 of $0.61 per diluted share. Included in second quarter results is $0.05 per diluted |
|
| July 27, 2011 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 27, 2011 Covance Inc. |
|
| June 29, 2011 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K (X) ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 OR ( ) TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-12213 A. Full title of the plan and address of the plan, |
|
| May 18, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 12, 2011 Covance Inc. |
|
| May 6, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2011 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 COVA |
|
| May 5, 2011 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 4, 2011 Covance Inc. |
|
| May 5, 2011 |
COVANCE REPORTS FIRST QUARTER REVENUE OF $502M, GAAP EPS OF $0.54, AND PRO FORMA EPS OF $0.60 Exhibit 99.1 PRESS RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FIRST QUARTER REVENUE OF $502M, GAAP EPS OF $0.54, AND PRO FORMA EPS OF $0.60 Princeton, New Jersey, May 4, 2011 — Covance Inc. (NYSE: CVD) today reported GAAP earnings for its first quarter ended March 31, 2011 of $0.54 per diluted share. Included in first quarter results is $0.06 per diluted share in c |
|
| April 19, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 25, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 25, 2011 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION SCHEDULE 13G SIGNATURE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Covance, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 222816100 (CUSIP Number) December 31, 2010 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 28, 2011 |
QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 28, 2011 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 21 COVANCE INC. |
|
| February 28, 2011 |
Exhibit 10.48 AMENDMENT NO. 1 COVANCE INC. SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN (As Amended and Restated January 1, 2009) WITNESSETH: WHEREAS, Covance Inc. (the “Company”) adopted the Covance Inc. Supplemental Executive Retirement Plan (the “SERP”), as amended and restated January 1, 2009, to provide supplemental retirement income to certain of its key executives; and WHEREAS, the Company desire |
|
| February 23, 2011 |
EX-10.4 5 a11-63631ex10d4.htm EX-10.4 Exhibit 10.4 [EMPLOYEE] [ADDRESS] [Grant Date: ] COVANCE INC. NON-QUALIFIED STOCK OPTION AWARD 20 Employee Equity Participation Plan NON-QUALIFIED STOCK OPTION AWARD granted by COVANCE INC., a Delaware Company (the “Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, to the “Employee”. A. WHEREAS, the Employee is now employed by the Company |
|
| February 23, 2011 |
Exhibit 10.3 COVANCE INC. RESTRICTED STOCK AGREEMENT 20 Employee Equity Participation Plan (20 [grant year] Award) RESTRICTED STOCK AGREEMENT dated as of [grant date] (the “Agreement”) between COVANCE INC., a Delaware corporation (“Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, and (the “Employee”). W I T N E S S E T H: A. WHEREAS, the Employee is currently employed by the |
|
| February 23, 2011 |
COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2011 Award) Exhibit 10.2 COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2011 Award) RESTRICTED STOCK AGREEMENT dated as of February 17, 2011 (the “Agreement”) between COVANCE INC., a Delaware corporation (“Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, and James W. Lovett (the “Employee”). W I T N E S S E T H: A. WHEREAS, the Employee is currently emp |
|
| February 23, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 16, 2011 Covance Inc. |
|
| February 23, 2011 |
COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2011 Award) Exhibit 10.1 COVANCE INC. RESTRICTED STOCK AGREEMENT 2010 Employee Equity Participation Plan (2011 Award) RESTRICTED STOCK AGREEMENT dated as of February 17, 2011 (the “Agreement”) between COVANCE INC., a Delaware corporation (“Company”), located at 210 Carnegie Center, Princeton, New Jersey 08540, and (the “Employee”). W I T N E S S E T H: A. WHEREAS, the Employee is currently employed by the Com |
|
| January 26, 2011 |
Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS FOURTH QUARTER REVENUE OF $492 MILLION, GAAP EPS OF $0.45, AND PRO FORMA EPS OF $0.56 — Issues 2011 Pro Forma EPS Range of $2.50 to $2.90 — Princeton, New Jersey, January 26, 2011 — Covance Inc. (NYSE: CVD) today reported GAAP earnings for its fourth quarter ended December 31, 2010 |
|
| January 26, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 26, 2011 Covance Inc. |
|
| January 14, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 10, 2011 Covance Inc. |
|
| January 5, 2011 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 31, 2010 Covance Inc. |
|
| January 5, 2011 |
AMENDMENT TO EMPLOYMENT LETTER AGREEMENT Exhibit 10.1 December 31, 2010 Joseph L. Herring AMENDMENT TO EMPLOYMENT LETTER AGREEMENT THIS AMENDMENT TO THE EMPLOYMENT LETTER AGREEMENT (this “Amendment”) made as of the 31st day of December, 2010 (the “Effective Date”) by and between Covance Inc. (hereinafter the “Company”) and Joseph L. Herring (hereinafter the “Executive” and together with the Company, the “Parties”). WITNESSETH: WHEREAS, t |
|
| January 5, 2011 |
AMENDMENT TO EMPLOYMENT LETTER AGREEMENT Exhibit 10.2 December 31, 2010 Form of amendment agreement for non CEO executive officers: [Richard F. Cimino, William Klitgaard, Michael J. Lehmann, James Lovett and Deborah Tanner] AMENDMENT TO EMPLOYMENT LETTER AGREEMENT THIS AMENDMENT TO THE EMPLOYMENT LETTER AGREEMENT (this “Amendment”) made as of the 31st day of December, 2010 (the “Effective Date”) by and between Covance Inc. (hereinafter t |
|
| December 29, 2010 |
Exhibit 10.1 December 20, 2010 Wendel Barr Re: Letter Agreement Dear Wendel: Pursuant to our discussions, below are the final terms of your resignation from Covance Inc. (“Covance”) effective after the end of December 31, 2010 (“Separation Date”). Please review this entire Letter Agreement, including the release language contained herein, and if you are satisfied with its contents, please sign and |
|
| December 29, 2010 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 23, 2010 Covance Inc. |
|
| November 23, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 18, 2010 Covance Inc. |
|
| November 12, 2010 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 8, 2010 Covance Inc. |
|
| November 12, 2010 |
Exhibit 10.1 EXECUTION VERSION November 8, 2010 Covance Inc. 210 Carnegie Center Princeton, New Jersey 08540 Ladies and Gentlemen: The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the Transaction entered into between J.P. Morgan Securities LLC, as agent for JPMorgan Chase Bank, National Association, London Branch (the “Seller”), and Covance Inc., |
|
| November 5, 2010 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2010 or o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 1-12213 |
|
| November 3, 2010 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 28, 2010 Covance Inc. |
|
| November 3, 2010 |
COVANCE REPORTS THIRD QUARTER FINANCIAL RESULTS AND TAKES ACTIONS TO STRENGTHEN FUTURE PERFORMANCE Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE Contact: Paul Surdez (609) 452-4807 www.covance.com COVANCE REPORTS THIRD QUARTER FINANCIAL RESULTS AND TAKES ACTIONS TO STRENGTHEN FUTURE PERFORMANCE Princeton, New Jersey, November 3, 2010 — Covance Inc. (NYSE: CVD) today reported results for its third quarter ended September 30, 2010, which included a GAAP loss of $0.49 per diluted share. Include |
|
| November 1, 2010 |
Exhibit 10.1 AMENDED AND RESTATED CREDIT AGREEMENT by and among COVANCE INC. and THE GUARANTORS PARTY HERETO and THE LENDERS PARTY HERETO and PNC BANK, NATIONAL ASSOCIATION, as Agent Dated as of October 26, 2010 PNC CAPITAL MARKETS, LLC, as Lead Arranger and Book Runner CITIBANK, N.A. JPMORGAN CHASE BANK, N.A. BANK OF AMERICA, N.A. TD BANK, N.A., as Co-Syndication Agents TABLE OF CONTENTS Section |
